Peptide Lab HQ Research Guide
B7-33
A research-focused compound profile covering B7-33 identity, relaxin B-chain analog research, RXFP1 receptor pathway models, fibrosis-related research context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | B7-33 |
|---|---|
| Common Research Name | Relaxin B-chain analog / RXFP1 agonist peptide |
| Compound Type | Synthetic single-chain relaxin mimetic / relaxin receptor research peptide |
| CAS Number | 1818415-56-3 |
| PubChem CID | 162662592 |
| Amino Acid Length | 26 amino acids |
| Amino Acid Sequence | Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu |
| Short Sequence | VIKLSGRELVRAQIAISGMSTWSKRSL |
| Molecular Formula | C₁₃₁H₂₂₉N₄₁O₃₆S; verify against supplier COA |
| Molecular Weight | Approximately 2986.58 g/mol; verify against supplier COA |
| Research Category | RXFP1 receptor signaling, relaxin pathway research, anti-fibrotic models, cardiac remodeling, pulmonary fibrosis, matrix metalloproteinase activity, ERK1/2 signaling, and tissue remodeling research |
| Research Context | Commonly discussed as a functionally selective RXFP1 agonist that retains relaxin-like anti-fibrotic pathway activity while showing limited cAMP activation in some research systems. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
B7-33 is commonly discussed in controlled research models involving RXFP1 receptor signaling, relaxin pathway activity, anti-fibrotic response, matrix metalloproteinase activity, cardiac remodeling, pulmonary fibrosis, tissue remodeling, ERK1/2 signaling, and extracellular matrix regulation.
RXFP1 Receptor Research
B7-33 is commonly studied as a functionally selective agonist of relaxin family peptide receptor 1, also known as RXFP1.
Relaxin Pathway Models
Used in research involving relaxin-like signaling, H2 relaxin comparison models, receptor activation, and downstream tissue-response pathways.
Anti-Fibrotic Research
B7-33 is commonly discussed in fibrosis-related models involving collagen deposition, extracellular matrix remodeling, and tissue stiffness observations.
Cardiac Remodeling Models
Published research has evaluated B7-33 in myocardial infarction, cardiomyopathy, left ventricular fibrosis, and adverse cardiac remodeling models.
Pulmonary Fibrosis Context
B7-33 has been studied in airway and lung remodeling research involving epithelial thickening, collagen deposition, and airway-function observations.
MMP / ERK Signaling Research
B7-33 is frequently discussed in relation to ERK1/2 activity, MMP-2 expression, collagen turnover, and RXFP1-associated matrix remodeling pathways.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on peptide purity, RXFP1 expression, study model, concentration, route, exposure duration, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 2 mg B7-33 |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 1 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 1 mg/mL, 1 unit equals 0.01 mg / 10 mcg B7-33. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Verify complete dissolution before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | B7-33, single-chain H2 relaxin B-chain-only analogue | B7-33 is commonly discussed as a relaxin mimetic peptide designed from the B-chain region of human H2 relaxin. |
| RXFP1 Receptor Research | Relaxin family peptide receptor 1 pathway context | Commonly discussed in RXFP1 binding, receptor activation, functionally selective signaling, pERK pathway activity, and relaxin-receptor research models. |
| Antifibrotic Research Context | Experimental and model-dependent context | B7-33 has been discussed in fibrosis-related research involving collagen turnover, matrix remodeling, MMP marker activity, cardiac fibrosis, renal fibrosis, and tissue-remodeling models. |
| Cardiovascular Research Context | Preclinical cardiac and vascular model context | Research discussions commonly include cardioprotection, myocardial injury models, adverse remodeling, left ventricular fibrosis, vascular function, and endothelial response markers. |
| Vasoprotective Research Context | Experimental vessel-function and endothelial-marker context | B7-33-related research has been discussed in vascular stiffness, endothelial function, vasorelaxation, nitric-oxide pathway context, and vascular-protection marker observations. |
| Functionally Selective Signaling | pERK-biased / reduced cAMP-style signaling context | Research references commonly distinguish B7-33 from full relaxin by discussing selective RXFP1 signaling patterns and pathway-specific endpoint tracking. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references may describe B7-33 in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, preclinical research references, public protocol-style references, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 2 mg | 2.0 mL | 1 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 1 mg/mL | U-100 Unit Reference | Approx. References per 2 mg Vial |
|---|---|---|---|
| 25 mcg | 0.025 mL | 2.5 units | 80 |
| 50 mcg | 0.05 mL | 5 units | 40 |
| 0.1 mg / 100 mcg | 0.10 mL | 10 units | 20 |
| 0.25 mg / 250 mcg | 0.25 mL | 25 units | 8 |
| 0.5 mg / 500 mcg | 0.50 mL | 50 units | 4 |
| 1 mg / 1000 mcg | 1.00 mL | 100 units | 2 |
| 2 mg / 2000 mcg | 2.00 mL | 200 units | 1 |
| 5 mg / 5000 mcg | 5.00 mL | 500 units | 0.4 |
| 10 mg / 10000 mcg | 10.00 mL | 1000 units | 0.2 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 25 mcg reference amount | 2.5 units / 0.025 mL |
| Standard Microgram Reference | Calculation reference only | 50 mcg reference amount | 5 units / 0.05 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.1 mg reference amount | 10 units / 0.10 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 25 units / 0.25 mL |
| Upper Conversion Example | Calculation reference only | 0.5 mg reference amount | 50 units / 0.50 mL |
| High Conversion Example | Calculation reference only | 1 mg reference amount | 100 units / 1.00 mL |
| 2 mg Preparation Reference | Preparation-level calculation reference | 2 mg reference amount | 200 units / 2.00 mL |
| 5 mg Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 500 units / 5.00 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 1000 units / 10.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for RXFP1 receptor activation, pERK pathway response, collagen-turnover markers, MMP markers, cellular-response, or pathway documentation depending on the model. |
| Acute Cardiovascular Observation Window | Single session to several days | Used for short-term vascular-response tracking, endothelial-marker comparison, receptor-response timing, or early pathway observation depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving fibrosis markers, vascular-response markers, cardiac-remodeling markers, or tissue-response endpoints. |
| Standard Protocol-Style Window | 4–8 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 8–12 weeks or longer | Used when longer documentation is needed for fibrosis-marker trends, cardiac-remodeling context, vascular-function markers, or follow-up marker tracking. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. B7-33 is commonly discussed in H2 relaxin B-chain-only analogue, RXFP1, functionally selective receptor signaling, pERK pathway, antifibrotic, vasoprotective, cardioprotective, endothelial-response, fibrosis-marker, and cardiac-remodeling research contexts. The selector above updates calculations for 2 mg and 10 mg vial references, each reconstituted with 2.0 mL bacteriostatic water. Published study references, preclinical research references, public protocol-style references, and wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
B7-33 is commonly discussed in research involving RXFP1 receptor activity, relaxin-like anti-fibrotic signaling, ERK1/2 pathway activation, MMP-2 expression, extracellular matrix remodeling, cardiac fibrosis, pulmonary fibrosis, and adverse tissue-remodeling models.
Study Limitations
B7-33 research is primarily preclinical and includes cell-culture systems, cardiac remodeling models, pulmonary remodeling models, and relaxin-pathway mechanistic studies. Findings should be interpreted according to model type, route, receptor expression, concentration, and study duration.
Safety Considerations
Research discussion should account for RXFP1 pathway activity, cardiovascular tissue-response context, peptide stability, route-specific uncertainty, sterility documentation, endotoxin risk, supplier qualification, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.